The follicular cell—derived thyroid cancers (termed nonmedullary thyroid cancers—NMTCs) occur mostly sporadically, but intriguingly, NMTC has the highest familial risk among all cancer sites. This epidemiological observation is strengthened by the clinical occurrence of NMTC in familial aggregation (FNMTC) and by the detection of chromosomal loci in linkage with the disease phenotype. FNMTC loci have been proposed at 14q, 1q21, 19p13.2, 2q21, 8p23, 8q24, 1q21, and 6q22, but to date, no causative mutations have been linked to FNMTCs. In this review, the authors focus on the clinical, morphological, and molecular aspects that characterize familial tumors. Some morphological patterns may alert for a familial disease. FNMTCs share several of the somatic molecular changes associated with sporadic tumors. New genes affected by somatic changes have been disclosed within regions harboring FNMTC loci.
Kraimps JL, Bouin-Pineau MH, Amati P., et al. Familial papillary carcinoma of the thyroid. Surgery. 1997;121:715-718.
2.
Suzuki S., Watanabe I.Familial occurrence of papillary thyroid carcinoma [in Japanese]. Gan No Rinsho. 1985;31: 414-419.
3.
Nemec J., Soumar J., Zamrazil V., Pohunkova D., Motlik K., Mirejovsky P.Familial occurrence of differentiated (nonmedullary) thyroid cancer. Oncology. 1975;32:151-157.
4.
Lote K., Andersen K., Nordal E., Brennhovd IOFamilial occurrence of papillary thyroid carcinoma. Cancer . 1980;46: 1291-1297.
5.
Cooper DS, Axelrod L., DeGroot LJ, Vickery AL Jr, Maloof F.Congenital goiter and the development of metastatic follicular carcinoma with evidence for a leak of nonhormonal iodide: clinical, pathological, kinetic, and biochemical studies and a review of the literature. J Clin Endocrinol Metab. 1981;52:294-306.
6.
Couch RM, Hughes IA, DeSa DJ, Schiffrin A., Guyda H., Winter JSAn autosomal dominant form of adolescent multinodular goiter. Am J Hum Genet. 1986;39:811-816.
7.
Stoffer SS, Van Dyke DL, Bach JV, Szpunar W., Weiss L.Familial papillary carcinoma of the thyroid. Am J Med Genet . 1986;25:775-782.
8.
Ozaki O., Ito K., Kobayashi K., Suzuki A., Manabe Y., Hosoda Y.Familial occurrence of differentiated, nonmedullary thyroid carcinoma. World J Surg. 1988;12:565-571.
9.
Gorson D.Familial papillary carcinoma of the thyroid. Thyroid. 1992;2:131-132.
10.
Phade VR, Lawrence WR, Max MHFamilial papillary carcinoma of the thyroid. Arch Surg. 1981;116:836-837.
Fischer DK, Groves MD, Thomas SJ Jr, Johnson PC Jr.Papillary carcinoma of the thyroid: additional evidence in support of a familial component. Cancer Invest. 1989;7: 323-325.
13.
Marchesi M. , Biffoni M., Biancari F., et al. Familial papillary carcinoma of the thyroid: a report of nine first-degree relatives of four families. Eur J Surg Oncol. 2000;26:789-791. 14. Rios A., Rodriguez JM, Illana J., Torregrosa NM, Parrilla P.Familial papillary carcinoma of the thyroid: report of three families. Eur J Surg. 2001;167:339-343.
14.
Marchesi M. , Biffoni M., Faloci C., Cresti R., Mariotti F., Gandini O.Familial papillary carcinoma of the thyroid: bio-genetic identification and clinical assessment of 4 families [in Italian] . Ann Ital Chir. 2001;72:267-272.
15.
Kwok CG, McDougall IRFamilial differentiated carcinoma of the thyroid: report of five pairs of siblings. Thyroid. 1995;5:395-397.
16.
Burgess JR, Duffield A., Wilkinson SJ, et al. Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid. J Clin Endocrinol Metab. 1997; 82:345-348.
17.
Lesueur F., Stark M., Tocco T., et al. Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium . J Clin Endocrinol Metab. 1999;84:2157-2162.
18.
Uchino S., Noguchi S., Kawamoto H., Yamashita H., Watanabe S., Shuto S.Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg. 2002;26:897-902. 20. Zivaljevic V., Paunovic I., Diklic A., et al. The incidence of familial nonmedullary thyroid cancer in a large case series. Acta Chir Belg. 2008;108:328-332.
19.
Ito Y., Fukushima M., Yabuta T., et al. Prevalence and prognosis of familial follicular thyroid carcinoma . Endocr J. 2008; 55:847-852.
Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MHSystematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994 ;86:1600-1608.
22.
Dong C., Hemminki K.Modification of cancer risks in offspring by sibling and parental cancers from 2,112,616 nuclear families. Int J Cancer. 2001;92:144-150.
23.
Galanti MR, Ekbom A., Grimelius L., Yuen J.Parental cancer and risk of papillary and follicular thyroid carcinoma. Br J Cancer. 1997;75:451-456.
24.
Hemminki K., Dong C.Familial relationships in thyroid cancer by histo-pathological type. Int J Cancer. 2000;85:201-205.
25.
Pal T., Vogl FD, Chappuis PO, et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab. 2001;86:5307-5312.
26.
Ron E., Kleinerman RA, Boice JD Jr, LiVolsi VA, Flannery JT, Fraumeni JF Jr.A population-based case-control study of thyroid cancer. J Natl Cancer Inst. 1987;79:1-12.
27.
Hemminki K., Eng C., Chen B.Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab. 2005;90: 5747-5753.
28.
Frich L., Glattre E., Akslen LAFamilial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway. Cancer Epidemiol Biomarkers Prev. 2001;10:113-117.
29.
Bignell GR, Canzian F., Shayeghi M., et al. Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer . Am J Hum Genet. 1997;61:1123-1130.
30.
Canzian F., Amati P., Harach HR, et al. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet. 1998;63:1743-1748.
31.
Malchoff CD , Sarfarazi M., Tendler B., et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab. 2000 ;85:1758-1764.
32.
McKay JD , Lesueur F., Jonard L., et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet. 2001;69:440-446.
33.
Cavaco BM, Batista PF, Sobrinho LG, Leite V.Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density SNP genome-wide linkage analysis. J Clin Endocrinol Metab. 2008;93:4426-4430.
34.
He H., Nagy R., Liyanarachchi S., et al. A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. Cancer Res. 2009;69:625-631.
35.
Suh I., Filetti S., Vriens MR, et al. Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNP array-based linkage analysis of 38 families . Surgery. 2009;146:1073-1080.
36.
Tsilchorozidou T., Vafiadou E., Yovos JG, et al. A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci. Thyroid. 2005;15:1349-1354.
37.
Cavaco BM, Batista PF, Martins C., et al. Familial nonmedullary thyroid carcinoma (FNMTC): analysis of fPTC/ PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. Endocr Relat Cancer. 2008;15:207-215.
38.
Neumann S., Willgerodt H., Ackermann F., et al. Linkage of familial euthyroid goiter to the multinodular goiter-1 locus and exclusion of the candidate genes thyroglobulin, thyroperoxidase, and Na+/I- symporter. J Clin Endocrinol Metab. 1999;84:3750-3756.
39.
Bevan S., Pal T., Greenberg CR, et al. A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: confirmation of linkage to TCO1 . J Clin Endocrinol Metab. 2001;86:3701-3704.
40.
McKay JD , Thompson D., Lesueur F., et al. Evidence for interaction between the TCO and NMTC1 loci in familial nonmedullary thyroid cancer. J Med Genet. 2004;41:407-412.
41.
Bonora E., Evangelisti C., Bonichon F., Tallini G., Romeo G.Novel germline variants identified in the inner mitochondrial membrane transporter TIMM44 and their role in predisposition to oncocytic thyroid carcinomas. Br J Cancer. 2006;95:1529-1536.
42.
Cetta F., Montalto G., Gori M., Curia MC, Cama A., Olschwang S.Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: results from a European cooperative study. J Clin Endocrinol Metab. 2000;85:286-292.
43.
Harach HR, Williams GT, Williams EDFamilial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology. 1994;25: 549-561.
44.
Liaw D., Marsh DJ, Li J., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16:64-67.
45.
Harach HR, Soubeyran I., Brown A., Bonneau D., Longy M.Thyroid pathologic findings in patients with Cowden disease. Ann Diagn Pathol. 1999;3:331-340.
46.
Ni Y., Zbuk KM, Sadler T., et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet . 2008;83:261-268.
47.
Stratakis CA , Courcoutsakis NA, Abati A., et al. Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex). J Clin Endocrinol Metab . 1997;82:2037-2043.
48.
Ishikawa Y. , Sugano H., Matsumoto T., Furuichi Y., Miller RW, Goto M.Unusual features of thyroid carcinomas in Japanese patients with Werner syndrome and possible genotype-phenotype relations to cell type and race. Cancer. 1999;85: 1345-1352.
49.
Congedo V., Celi FSThyroid disease in patients with McCune-Albright syndrome. Pediatr Endocrinol Rev. 2007; 4(suppl 4):429-433.
50.
Mastorakos G., Mitsiades NS, Doufas AG, Koutras DAHyperthyroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report . Thyroid. 1997;7:433-439.
51.
Collins MT, Sarlis NJ, Merino MJ, et al. Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. J Clin Endocrinol Metab . 2003;88:4413-4417.
52.
Malchoff CD, Sarfarazi M., Tendler B., Forouhar F., Whalen G., Malchoff DMFamilial papillary thyroid carcinoma is genetically distinct from familial adenomatous polyposis coli. Thyroid. 1999;9:247-252.
53.
Eng C.Familial papillary thyroid cancer: many syndromes, too many genes?J Clin Endocrinol Metab. 2000;85:1755-1757.
54.
Sobrinho-Simoes M., Maximo V., Rocha AS, et al. Intragenic mutations in thyroid cancer . Endocrinol Metab Clin North Am. 2008;37:333-362, viii.
55.
Grieco M., Santoro M., Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990;60:557-563.
56.
Bongarzone I., Vigneri P., Mariani L., Collini P., Pilotti S., Pierotti MARET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res. 1998;4: 223-228.
57.
Bongarzone I., Fugazzola L., Vigneri P., et al. Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma . J Clin Endocrinol Metab. 1996;81:2006-2009.
58.
Fenton CL, Lukes Y., Nicholson D., Dinauer CA, Francis GL, Tuttle RMThe ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab. 2000;85:1170-1175.
59.
Bounacer A. , Wicker R., Caillou B., et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene. 1997;15:1263-1273.
60.
Rabes HM, Demidchik EP, Sidorow JD, et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res. 2000 ;6:1093-1103.
61.
Castro P., Rebocho AP, Soares RJ, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:213-220.
62.
Kroll TG, Sarraf P., Pecciarini L., et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected] . Science. 2000;289:1357-1360.
63.
Soares P., Trovisco V., Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22:4578-4580.
64.
Trovisco V. , Soares P., Preto A., et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch. 2005;446:589-595.
65.
Charkes NDOn the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. Thyroid. 2006;16:181-186.
66.
Cetta F., Chiappetta G., Melillo RM, et al. The ret/ptc1 oncogene is activated in familial adenomatous polyposis-associated thyroid papillary carcinomas. J Clin Endocrinol Metab. 1998;83:1003-1006.
67.
Schuetze D. , Hoschar AP, Seethala RR, Assaad A., Zhang X., Hunt JLThe T1799A BRAF mutation is absent in cribriform-morular variant of papillary carcinoma. Arch Pathol Lab Med. 2009;133:803-805.
68.
Brunaud L., Zarnegar R., Wada N., et al. Chromosomal aberrations by comparative genomic hybridization in thyroid tumors in patients with familial nonmedullary thyroid cancer. Thyroid. 2003;13:621-629.
69.
Prazeres HJ , Rodrigues F., Soares P., et al. Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinoma . Fam Cancer. 2008;7:141-149.
70.
Stankov K., Pastore A., Toschi L., et al. Allelic loss on chromosomes 2q21 and 19p 13.2 in oxyphilic thyroid tumors. Int J Cancer. 2004;111:463-467.
71.
Maximo V., Botelho T., Capela J., et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer. 2005;92:1892-1898.
72.
Kalakonda S. , Nallar SC, Lindner DJ, Hu J., Reddy SP, Kalvakolanu DVTumor-suppressive activity of the cell death activator GRIM-19 on a constitutively active signal transducer and activator of transcription 3. Cancer Res. 2007;67:6212-6220.
73.
Gasparre G. , Porcelli AM, Bonora E., et al. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors . Proc Natl Acad Sci U S A. 2007;104:9001-9006.
74.
Lima J., Teixeira-Gomes J., Soares P., et al. Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia. J Clin Endocrinol Metab. 2003;88:4932-4937.
75.
Liu CX, Musco S., Lisitsina NM, Forgacs E., Minna JD, Lisitsyn NALRP-DIT, a putative endocytic receptor gene, is frequently inactivated in non-small cell lung cancer cell lines. Cancer Res. 2000;60:1961-1967.
76.
Liu CX, Musco S., Lisitsina NM, Yaklichkin SY, Lisitsyn NAGenomic organization of a new candidate tumor suppressor gene, LRP1B. Genomics. 2000;69:271-274.
77.
Liu CX, Li Y., Obermoeller-McCormick LM, Schwartz AL, Bu G.The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein. J Biol Chem. 2001;276:28889-28896.
78.
Ito Y., Kakudo K., Hirokawa M., et al. Biological behavior and prognosis of familial papillary thyroid carcinoma. Surgery. 2009;145:100-105.
79.
Grossman RF , Tu SH, Duh QY, Siperstein AE, Novosolov F., Clark OHFamilial nonmedullary thyroid cancer: an emerging entity that warrants aggressive treatment. Arch Surg. 1995;130: 892-897; discussion 8-9.
80.
Sturgeon C., Clark OHFamilial nonmedullary thyroid cancer. Thyroid. 2005;15:588-593.
81.
Alsanea O., Wada N., Ain K., et al. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery . 2000;128:1043-1050; discussion 1050-1051.
82.
Uchino S., Noguchi S., Yamashita H., et al. Detection of asymptomatic differentiated thyroid carcinoma by neck ultrasonographic screening for familial nonmedullary thyroid carcinoma . World J Surg. 2004;28:1099-1102.
83.
Loh KCFamilial nonmedullary thyroid carcinoma: a meta-review of case series. Thyroid. 1997;7:107-113.
84.
Maxwell EL, Hall FT, Freeman JLFamilial non-medullary thyroid cancer: a matched-case control study. Laryngoscope. 2004;114:2182-2186.
85.
Triponez F. , Wong M., Sturgeon C., et al. Does familial nonmedullary thyroid cancer adversely affect survival? World J Surg. 2006;30:787-793.
86.
Musholt TJ, Musholt PB, Petrich T., Oetting G., Knapp WH, Klempnauer J.Familial papillary thyroid carcinoma: genetics, criteria for diagnosis, clinical features, and surgical treatment. World J Surg. 2000;24:1409-1417.
87.
Capezzone M. , Marchisotta S., Cantara S., et al. Familial nonmedullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. Endocr Relat Cancer. 2008;15:1075-1081.
88.
Cameselle-Teijeiro J., Chan JKCribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma? Mod Pathol. 1999;12:400-411.
89.
Leprat F., Bonichon F., Guyot M., et al. Familial non-medullary thyroid carcinoma: pathology review in 27 affected cases from 13 French families. Clin Endocrinol (Oxf). 1999;50: 589-594.
90.
Katoh R., Harach HR, Williams EDSolitary, multiple, and familial oxyphil tumours of the thyroid gland. J Pathol. 1998; 186:292-299.
91.
Mosso L., Velasco S., Salazar I., et al. Clinical features of 17 patients with familial non medullary thyroid carcinoma [in Spanish]. Rev Med Chil. 2007;135:718-724.
92.
Tomer Y., Barbesino G., Greenberg DA, Concepcion E., Davies TFLinkage analysis of candidate genes in autoimmune thyroid disease. III. Detailed analysis of chromosome 14 localizes Graves’ disease-1 (GD-1) close to multinodular goiter-1 (MNG-1). International Consortium for the Genetics of Autoimmune Thyroid Disease. J Clin Endocrinol Metab. 1998;83:4321-4327.
93.
Tomer Y., Ban Y., Concepcion E., et al. Common and unique susceptibility loci in Graves and Hashimoto diseases: results of whole-genome screening in a data set of 102 multiplex families. Am J Hum Genet. 2003;73:736-747.
94.
Vierimaa O. , Georgitsi M., Lehtonen R., et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312:1228-1230.
